Stifel Reiterates Hold Rating on Biogen (BIIB), Views lecanemab Readout as "Risky"
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $230.00 price target on Biogen (NASDAQ: BIIB), following the company's Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
